West Pharmaceutical Services Raises 2026 Sales Guidance After 21% Q1 Revenue Surge
West Pharmaceutical Services posted first-quarter net sales of $844.9 million, a 21.0% increase (15.3% organic), and diluted EPS of $1.92, up 56.1%, driving operating cash flow of $89.9 million and free cash flow of $47.2 million. It raised 2026 sales guidance to $3.295 billion–$3.350 billion and adjusted EPS to $8.40–$8.75.
1. Q1 Financial Performance
West Pharmaceutical Services reported first-quarter net sales of $844.9 million, up 21.0% year-over-year (15.3% organic). Diluted EPS was $1.92, a 56.1% increase, and adjusted EPS was $2.13, up 46.9%, while operating cash flow reached $89.9 million and free cash flow totaled $47.2 million.
2. Share Repurchase Program
The company repurchased 1.2 million shares for $297.6 million at an average price of $243.57 per share since mid-February under its share repurchase program.
3. Guidance Increase
Full-year 2026 net sales guidance was increased to $3.295 billion–$3.350 billion (from $3.215 billion–$3.275 billion) and adjusted EPS guidance was raised to $8.40–$8.75 (from $7.85–$8.20). Second-quarter sales are expected at $830 million–$850 million with adjusted EPS of $2.05–$2.12.
4. Segment Highlights
In its Proprietary Products segment, net sales rose 23.3% to $694.3 million, driven by a 29.6% increase in High-Value Product Components and 29.0% growth in Delivery Devices. Standard Products grew 6.7% to $161.4 million, and its West Vantage segment delivered $150.6 million in revenue, up 11.6%.